Medscape7h
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
Managed Healthcare Executive3h
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
pharmaphorum1d
First biosimilar fast-acting insulin reaches US market
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Medscape1d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
MedPage Today4d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Monthly Prescribing Reference1d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets™
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...
The Pharma Letter2d
FDA nod for first rapid-acting insulin biosimilar
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...
Pharm Exec2d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...